Archive for 'Publications' Category
I’m presenting a couple of posters at the International Society of Pharmacovigilance Conference this week. One is concerned with possible neuropsychiatric reactions to varenicline, and the other uses the DoTS ADR classification system to analyse reports of angioedema with angiotensin-II receptor antagonists. Further details at the links in the text.
Here is a link to a Pharmaceutical Journal article about pharmacovigilance a colleague and I wrote. Dr Davies was the lead author of the recent PLoS One paper on in-patient adverse drug reactions. It’s slightly parochial, being a response to Royal Pharmaceutical Society of Great Britain report on drug safety, but does tackle the perhaps […]
I have a new article in The Pharmaceutical Journal published with a colleague Dr Deborah Layton looking at the neuraminidase inhibitors oseltamivir and zanamivir. Cox A, Layton D. Adverse drug reactions: Neuraminidase inhibitors: widespread use for influenza may reveal more adverse effects. The Pharmaceutical Journal 2009; 282:621-622 The neuraminidase inhibitors (NAIs), oseltamivir (Tamiflu) and zanamivir […]
I have written a brief review of patient reporting of adverse drug reactions by patients for Pharmacovigilance Review. It’s not a systematic review, but I think it is a reasonable review of current knowledge. The PDF is here.
Here’s a paper in the The British Journal of Diabetes & Vascular Disease I’ve just published with a colleague about prescribing errors in diabetes that may be of interest to some readers. Prescribing errors in diabetes have the potential to cause serious adverse effects. Antidiabetic agents are a significant cause of admission to hospital. Prescribing […]
Deborah Layton and I have a brief article in The Pharmaceutical Journal this week on the subject of antispychotics and the evidence for the risk of stroke associated with their use. Layton D, Cox A. Antipsychotics and stroke: the story to date. The Pharmaceutical Journal 2009; 282: 30 You have to register to read it.
Cox A. Involving patients in reporting adverse drug reactions should be welcomed. The Pharmaceutical Journal 2009; 282: 16-17 Patients are no longer the passive recipients of drug therapy instigated by medical professionals. There is increasing patient engagement in individual decisions about their own drug therapy, public discussions about the provision of high cost drugs in […]
Because all medicines have the potential to cause adverse effects, the safety of prescribed medicines is a central concern for health professionals. The initial decision to resort to pharmacological treatment, the choice of drug, and the management and monitoring of the patient require knowledge of drug-induced disease. Additionally, a wider public health duty exists for […]
I have published a short review of Mann’s Pharmacovigilance at The Pharmaceutical Journal.